Document is current
Any future updates will be listed below
-
Authors
Li, Amanda M. https://orcid.org/0000-0001-8099-9501
Aftandilian, Catherine
Annesley, Colleen
Colace, Susan
Faulk, Kelly E.
Goldman, Joshua W.
Guest, Erin https://orcid.org/0000-0003-2482-5608
Hayani, Ammar
Ho, Richard
Jabbour, Elias https://orcid.org/0000-0003-4465-6119
Khanna-Farber, Anjali
Kyono, Wade
Leger, Kasey
Maloney, Kelly
McCall, David https://orcid.org/0000-0003-2297-9670
Miller, Tamara
Pacenta, Holly L.
Quigg, Troy C.
Rubinstein, Jeremy D.
Schafer, Eric
Rheingold, Susan R. https://orcid.org/0000-0001-8025-6767
Bhojwani, Deepa https://orcid.org/0000-0002-7559-7927
O’Brien, Maureen M.
Rabin, Karen R. https://orcid.org/0000-0002-4081-8195
- License Information
-
More Information
Article History
Received: 31 December 2025
Revised: 8 April 2026
Accepted: 15 May 2026
First Online: 3 June 2026
Competing interests
: EG – Amgen (employment, stock); KL – Jazz Pharmaceuticals (consultant), Servier (consultant); DM – Abbvie (research funding), Crossbow Therapeutics (research funding), Kura Oncology (research funding), Gateway for Cancer Research (research funding), MD Education (travel accommodations and speaker honorarium), Servier (research funding); TCQ – Jazz Pharmaceuticals (speaker’s bureau); SRR – Pfizer (consultant), AbbVie (consultant); DB – Wugen (research funding); MMO’B – Pfizer (research funding and consultant). The remaining authors declare no competing financial interests.
